Livagen
Lys-Glu-Asp-Ala tetrapeptide (KEDA)
No human clinical trials have been conducted. All evidence comes from animal or laboratory studies.
A synthetic short peptide studied mainly in laboratory experiments with elderly human immune cells and animal liver tissue, where it appears to reactivate genes that had been switched off during aging. No human clinical trials have been conducted, so its safety and effectiveness in people are unknown.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
No peer-reviewed safety data, dedicated toxicology studies, FDA labels, or FAERS case records exist for Livagen. All side effect information above comes from vendor pages and community anecdotes, which are not substitutes for clinical pharmacovigilance. Peptide Initiative reports adverse events in less than 5% of patients from Eastern European clinical use spanning 20+ years, but this claim could not be verified against primary clinical data. Preclinical rodent studies reportedly showed no observable toxic effects at low-to-moderate doses with repeated dosing for up to 30 days. One online communities user reported severe anxiety and cardiac palpitations lasting several months after a 12-day protocol. No data on drug-drug interactions, pharmacokinetics, or carcinogenic risk exists. The absence of carcinogenicity or mutagenicity data is a notable gap given that the peptide's mechanism involves chromatin remodeling which could theoretically unmask oncogenes.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-20]